Dr. Martens Reaffirms FY2027 Outlook on Strong US Wholesale Demand

Dr. Martens (LON:DOCS) reaffirmed its financial outlook for fiscal year 2027 on Wednesday, citing encouraging signs from wholesale demand in the United States, its largest single market. The British footwear brand said that trading since its financial year began in April has been in line with its expectations.

Guidance Maintained

The company's outlook for fiscal 2027 remains unchanged, according to a statement released Wednesday. Based on a company-compiled consensus, Dr. Martens expects to report an adjusted pretax profit of £68 million (approximately $91.21 million) for the fiscal year.

This reaffirmation suggests management confidence in its strategy despite mixed economic signals across its global markets.

Performance by Region

The positive outlook is primarily underpinned by what the company described as encouraging wholesale demand in the U.S. This market is a critical driver of revenue and profitability for the brand.

Ad

Performance in other key areas also contributed to the steady trading update:

• Japan and South Korea were reported to be "performing well."
• European markets met expectations, even amid what the company described as a "challenging consumer backdrop."

Broader Context

This update provides a measure of stability for investors following a previous report in May, where Dr. Martens had noted a revenue decline in its Europe, Middle East and Africa (EMEA) region.

At that time, the company had attributed the weakness in the EMEA region to the economic fallout from geopolitical events weighing on consumer spending. The latest announcement indicates that performance in the new fiscal year has so far met internal forecasts.